Alvimopan retains efficacy in patients undergoing colorectal surgery within an established ERAS program

Area of Science:

• Colorectal Surgery
• Gastrointestinal Function
• Enhanced Recovery After Surgery (ERAS) Protocols

Background:

• Post-operative ileus and delayed gastrointestinal function are common after colorectal surgery.
• Enhanced Recovery After Surgery (ERAS) protocols often use alvimopan to counteract opioid effects and lidocaine for analgesia.
• Limited data exist on alvimopan's effectiveness in opioid-sparing regimens.

Purpose of the Study:

• To evaluate the efficacy of alvimopan and lidocaine in enhancing gastrointestinal recovery post-colorectal surgery.
• To determine the impact of alvimopan and lidocaine on time to first bowel movement and length of hospital stay within an ERAS protocol.

Main Methods:

• Retrospective cohort analysis of 192 adult patients undergoing colorectal resection.
• Patients were grouped based on the administration of alvimopan (A/a) and/or lidocaine (L/l).
• Primary endpoint: median time to first bowel movement or discharge; Secondary endpoint: length of stay.

Main Results:

• A significant difference in median time to bowel movement or discharge was observed among the four groups (p=0.001).
• Alvimopan (AL and Al groups) significantly reduced time to GI recovery compared to no alvimopan (aL group).
• Length of stay was significantly reduced by 1.8 days in groups receiving alvimopan (AL and Al) compared to the no-alvimopan group (aL).

Conclusions:

• Alvimopan significantly improves time to gastrointestinal recovery and reduces length of stay in ERAS programs.
• The combination of alvimopan and lidocaine yielded the greatest reduction in time to GI recovery and length of stay.
• Alvimopan demonstrates efficacy in opioid-sparing ERAS protocols for colorectal surgery.